Phospholipid Research Center | Announcement
archive,category,category-announcement,category-96,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-15.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

FDA Press Announcement, August 4th, 2017   Vyxeos™   Vyxeos™ (daunorubicin and cytarabine) represents the first new chemotherapy advance in more than 40 years for these adults with AML. It is a liposome formulation of a fixed combination of daunorubicin and cytarabine for intravenous infusion. Vyxeos is indicated for...